Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma
Conditions
Keywords
Adoptive Cell Transfer, Lymphocytes, Tumor-Infiltrating, Interleukin-2, Melphalan, Antineoplastic Agents, Immunological, Hepatic arterial infusion, bioreactor
Brief summary
The purpose of this study is to evaluate the feasibility, safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion in patients with liver metastases (including but not restricted to) of malignant melanoma.
Interventions
Administered via hepatic arterial infusion
DRUGMelphalan
Melphalan will be administered once as an intravenous infusion.
DRUGInterleukin-2
After TIL infusion, Interleukin-2 will be administered subcutaneously once daily for up to 14 days.
Sponsors
Miltenyi Biomedicine GmbH
Vastra Gotaland Region
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
dose escalation
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients 18-75 years of age on the day of signing informed consent. 2. Patient is willing and able to provide written informed consent and comply with study procedures. Written informed consent must be signed and dated before the start of specific protocol procedures. 3. Patient must have a histologically/cytologically confirmed diagnosis of: * stage IV uveal melanoma with or without any previous systemic therapy OR * stage IV cutaneous melanoma with confirmed progression following at least one or two prior systemic therapies including a programmed cell death protein-1 (PD-1) inhibitor with or without a CTLA-4 inhibitor; and if BRAF V600 mutation-positive, also a BRAF inhibitor or a BRAF inhibitor in combination with a MEK inhibitor. 4. Measurable disease by computed tomography (CT) per RECIST 1.1 criteria with at least one target lesion identified in the liver and where the distribution pattern of metastasis is predominantly engaging the liver as judged by the investigator. 5. At least one resectable lesion in the liver (or aggregate of lesions resected) of a minimum size of 0.5 cm in diameter post- resection to generate TILs. 6. ECOG performance status of 0 - 2. 7. Female patient of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 8. Female patients of childbearing potential must be willing to use a highly efficient method of contraception (Pearl index \<1), for the course of the study through 120 days after the last dose of study medication. 9. Male patients with women of childbearing potential partners must agree to use a condom for contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.
Exclusion criteria
1. Life expectancy of less than 3 months. 2. History of interstitial lung disease (ILD) or (non-infectious) pneumonitis. 3. Reduced renal function defined as S- Creatinine \>=1.5xULN or Creatinine Clearance \< 40 mL/min, calculated using the Cockroft and Gault formula. 4. Reduced hepatic function (defined as ASAT, ALAT, bilirubin \> 3\*ULN and PK- INR \> 1.5) or medical history of liver cirrhosis or portal hypertension. 5. Hemoglobin \<90 g/L or platelets \<100x109/L or neutrophils \<1.5x109/L 6. Use of live vaccines four weeks before or after the start of study. 7. History of severe hypersensitivity reactions to monoclonal antibodies. 8. Active infection. 9. Infection of human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), hepatitis B or hepatitis C. 10. Active autoimmune disease or a history of known or suspected autoimmune disease. 11. A condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses \>10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. 12. Concomitant therapy with any other anti- cancer therapy, concurrent medical conditions requiring use of immunosuppressive medications or use of other investigational drugs. 13. Has a known additional malignancy of other diagnosis that is progressing or requires active treatment. 14. Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study drug. 15. A history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) | 5 years from start of chemotherapy | Adverse events are graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical benefit rate (CBR) | 18 weeks | Defined by RECIST 1.1 |
| Progression free survival (PFS) | 2 years | Evaluation of progression-free survival |
| hepatic Progression free survival (hPFS) | 2 years | Evaluation of hepatic progression-free survival |
| Objective response rate (ORR) | 2 years from start of chemotherapy | Defined by RECIST 1.1 |
| Overall Survival (OS) | 5 years | Evaluation of overall survival |
| Evaluation of feasibility of an automated production of TILs | 2 years | Defined as the proportion of patients included that receive treatment with the TIL product. |
| Duration of objective response (DOR) | 2 years | Evaluation of duration of response |
Countries
Sweden
Outcome results
None listed